Chemotherapy and radiation can be so toxic to the human body that some cancer patients choose to halt treatment rather than live through one more day of pain and misery. Traditional medicine’s standard cancer treatment weapons — chemotherapy and radiation — work by flooding the body with aggressively toxic chemicals or battering it with caustic radiation. The problem is that while these traditional cancer therapies do kill cancer cells, they also kill healthy cells, weakening and even damaging the body. For many cancer patients the physical and emotional cost of chemotherapy or radiation is simply too great. Alternative cancer therapies offer effective non-toxic cancer treatment options that work with the body to battle cancer.
Issels autologous cancer vaccines are prepared from the patient’s own blood to be non-toxic and immediately compatible with the patient’s system. Our cancer vaccines work with the body’s immune system to strengthen the patient’s natural immunity against cancer cells. Every day we are exposed to all sorts of bacteria, viruses, pollutants, diseases and other potentially hazardous elements. As these agents invade our bodies, our immune system goes on the attack, producing disease-fighting antibodies. These antibodies remain in the blood stream, our immune system responds and creates a powerful barrier to future exposure.
Issels cancer vaccines work in much the same way. Prepared from the patient’s own blood, Issels autologous cancer vaccines intensify immune system response and enhance the body’s ability to fight cancer.
The traditional cancer treatment community has been excited by news that an experimental cancer vaccine has successfully used cells from the patients’ own immune systems to slow the production of cancer cells in six of seven patients with advanced melanoma. In explaining the procedure, Medical Daily suggested that personalized immunotherapy “may represent the future of cancer treatment.”
We suggest the future is now! While the experimental cancer vaccine developed by researchers at the Washington University School of Medicine in St. Louis may seem like it is breaking new ground to practitioners of traditional Western medicine, Issels Integrated Oncology has been incorporating immune-boosting cancer vaccines with similar properties into our personalized integrative immunotherapy treatments for more than 60 years.
Washington University’s vaccine used dendritic immune system cells in the patients’ skin to boost their immune response. As we note on our website, dendritic cells are key regulators of the immune responses. Vital in the identification of damaging pathogens that invade the body, including malignant cancer cells, dendritic cells trigger antigens in the immune system to multiply and attack disease; in this way boosting immune response to cancer cells.
Washington University researchers estimate that it could be more than a decade before they are able to develop a marketable vaccine; but Issels already offers two dendritic cell-driven cancer vaccines:
Extracorporeal Photopheresis with the Autologous Dendritic Cell Vaccine
Autologous Dendritic Cell Vaccine
Visit our website for more detailed information about the cancer vaccines we offer and what they do. A powerful cancer-fighting tool, our cancer vaccines work with the body, strengthening and harnessing the patient’s own immune system to destroy cancer cells. Our personalized immunotherapy cancer treatment program has proven successful in achieving long-term cancer remissions for many of our patients. Why wait; contact us today to learn more about Issels alternative cancer treatments.
An experimental cancer vaccine that harnesses the patient’s immune system is being hailed as the future of cancer treatment. In recently published studies conducted by researchers at the Washington University School of Medicine in St. Louis, six of seven cancer patients with advanced Stage IV melanoma responded positively to a cancer vaccine that used cells from each patient’s own immune system to attack and slow the reproduction of cancer cells. In three patients, the vaccine also slowed tumor development.
Lead researcher Dr. Gerald Linette called the experimental cancer treatment approach “personalized immunotherapy.” Telling U.S. News, “This is going to end up being the way we cure cancer,” Dr. Michele Green, a dermatologist at New York City’s Lenox Hill Hospital, predicted that personalized immunotherapy and individualized cancer vaccines will become standard treatment protocols for cancers of all types in the future.
While the remarkable success of this experimental cancer vaccine may seem new and exciting to practitioners of traditional Western medicine, Issels Integrative Oncology cancer treatment centers have been using personalized cancer vaccines to successfully treat various types of cancer for decades. Typically used in conjunction with our personalized immunobiologic core cancer treatment, Issels’ vaccine program is designed to strengthen the individual patient’s immune system and use it to target the tumor microenvironment.
Research findings have confirmed the vital importance of tumor microenvironments in directing the regression or progression of cancer. As Issels’ 60 years of clinical experience with integrative immunotherapy has shown, the ability to manipulate tumor microenvironments has a profound influence on the outcome of cancer treatments.
Next time: Are new cancer vaccines really breaking new ground?